FDA Approves Pfizer's Biosimilar, RUXIENCE, for Certain Cancers and Autoimmune Condition
July 23, 2019
July 23, 2019
NEW YORK, July 23 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE(TM) (rituximab-pvvr), a biosimilar to Rituxan(R) (rituximab),/1 for the treatment of adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)./2
"Biosi . . .
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE(TM) (rituximab-pvvr), a biosimilar to Rituxan(R) (rituximab),/1 for the treatment of adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)./2
"Biosi . . .